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Abstract 
Fluorination reactions of medicinal and biologically-active compounds will be discussed. Late stage 
fluorination strategies of medicinal targets have recently attracted considerable attention on account 
of the influence that the fluorine atom can impart to targets of medicinal importance, such as a 
modulation of lipophilicity, electronegativity, basicity and bioavailability, this latter as a 
consequence of membrane permeability. Therefore, the recourse to late-stage fluorine substitution on 
compounds with already known and relevant biological activity can provide the pharmaceutical 
industry with new leads with improved medicinal properties. The fluorination strategies will take 
into account different fluorinating reagents, nucleophilic, electrophilic and of radical nature. Diverse 
families of organic compounds such as (hetero)aromatic rings, and aliphatic substrates (sp
3
, sp
2
, and 
sp carbon atoms) will be studied in late-stage fluorination reaction strategies. 
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1.-Introduction 
There are several recent review articles 
1
 and comprehensive books 
2
 that deal with fluorine-
containing drugs for human use. The benefits of introducing a fluorine atom into the organic 
backbone of a pharmacophore is well understood and has been underscored 
3
 in reports dealing with 
fluorine in pharmaceuticals and in medicinal chemistry in general. 
1b-o
 A brief historical overview of 
fluorine in chemistry and medicinal chemistry has recently been described. 
1b,c,e
 
 The omniphobicity/lipophilicity and electrostatic interactions can be considered among the 
most prominent effects. Thus, introducing fluorine into an organic compound can significantly alter 
its biological properties. 
 One other subtle but important effect of introducing fluorine into the backbone of a medicinal 
target is the inflection of acidity and basicity of the parent compound 
4
, which can change, inter alia, 
the binding affinity, and bioavailability. Highly basic groups can have a detrimental effect on the 
bioavailability of a drug. Thus introducing a fluorine atom next to a basic group can reduce its 
basicity, enhancing its membrane permeability, and increasing bioavailability. Although the 
replacement of hydrogen for fluorine does not have a profound steric influence, electrostatic 
interactions with other groups can change conformations significantly.
1o,5,6
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 The replacement of hydrogen for fluorine on aromatic rings is a well-known strategy to 
decelerate oxidative metabolic processes by Cytochrome P450 monooxygenases. In this respect, the 
electron-withdrawing properties of fluorine on aromatic rings, which can slow down hydrolytic 
metabolism, alter reaction rates and stability of intermediates. Fluorine substitution on aromatic rings 
is also known to increase binding affinity, as a result of enhancing electrostatic interactions. 
However, it is difficult to predict the influence of fluorine substitution on the overall profile in a 
given situation.  
 As numerous reports attest 
1
, the number of marketed drugs that contain a fluorine atom has 
increased rapidly. As of 2009, the FDA-had approved >140 fluorine-containing drugs. 
7
 Many of the 
approved fluorinated drugs have multibillion dollar revenues, and considered among the most-
successful drugs (Figure 1) .  
 
 
 
Figure 1. Structures of atorvastatin, fluoxetin and ciprofloxaxin 
 
The rapid development of synthetic methodologies in organic fluorine chemistry 
1n
 and the 
increased understanding of the impact of fluorination on biological properties 
8
 have made possible 
the design and synthesis of structurally-diverse and sophisticated drug candidates. 
This review article is intended to present new synthetic methodologies 
9
 for accomplishing 
fluorination reactions on molecules (drugs/prodrugs) with pharmacological activity. It is not our aim 
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to describe, or enumerate fluorine-containing drugs and their mechanism of action.
1,10
 
Trifluoromethylation, trifluoromethoxylation, and trifluoromethylthiolation strategies will not be 
considered in this review. 
From the chemistry perspective, fluorinated pharmacologically-active drugs contain the 
fluorine atom in phenyl rings, heterocyclic rings, steroids and derivatives, for which synthetic late-
stage strategies for introducing fluorine can take into account homolytic and ipso aromatic 
substitutions on phenyl and heteroaromatic rings, and substitutions at sp
3
, sp
2
 C-H bonds in aliphatic 
compounds.  
 An area of rapid development is the synthesis of new and improved 
18
F –labeled compounds 
for applications in positron emission tomography.
11
 This area, deserves particular and detailed 
attention due to the short half-life of 
18
F (109.8 min) and will not be the subject of this review 
12a,b
, 
except where traditional and 
18
 F protocols overlap. 
15
 
 
2.-Fluorinating Reagents Used in Medicinal Chemistry 
16
 
 Examples of nucleophilic reagents employed to construct C–F bonds (Figure 2) include 
diethylaminosulfur trifluoride 1 (DAST) 
17
, 2,2-difluoro-1,3-dimethylimidazolidine 2 (DFI) 
18
, and 
bis(2-methoxyethyl) aminosulfur trifluoride 3 (Deoxofluor).
19
 Triethylamine trihydrofluoride 4 
(TREAT-HF), 
20
 has been used as a highly polar fluorinating reagent. More classical fluorinating 
reagents include CsF used at elevated temperatures in SNAr reactions or anhydrous tetramethyl 
ammonium fluoride 
21
, AgF, and AgF2. 
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Figure 2. Nucleophilic fluorinating reagents 
 
The development of electrophilic 
22
 fluorinating agents to tame the reactivity of elemental 
fluorine resulted in a great advancement. 
23
 A large array of electrophilic reagents 
24
 bearing a R2N–F 
or R3N
+–
 F unit has already been developed and commercialized (Figure 3), elaborated from the first 
such agent, Olah`s reagent (pyridinium poly(hydrogen fluoride) PPHF), N-fluoropyridinium triflate 5 
(developed by Umemoto
24b-d
), 2,4,6-trimethyl-1-fluoropyridinium triflate 6 (FP-T300,), introduced 
by Shibata. 
25,26
. However, the syntheses of all these (commercial) electrophilic reagents require the 
initial handling of fluorine gas. Among more recent electrophilic reagents are 1-chloromethyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 7 (Selectfluor) 
11
, 1-chloromethyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(hexafluorophosphate) 8 (FTEDA-PF6), 1-methyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 9 (Selectfluor II), 1-methyl-4-fluoro-
1,4-diazoniabicyclo[2.2.2]octane bis(hexafluorophosphate) 10 (Selectfluor II-PF6), and N-
fluorobenzenesulfonimide 11 (NFSI)
27
, or the methyl analog Me-NFSI 12 
28
, or 1-fluoro-4-hydroxy-
1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 13 (NFTh), developed by Stavber 
29
 and 
fluorobenziodoxole 14 (1-fluoro-1,3-dihydro-3,3-dimethyl-1,2-benziodoxle), reported in 2013 by 
Togni and Stuart 
30
 (Figure 3). 
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Figure 3. Electrophilic fluorinating reagents 
 
 Other recently introduced reagents, particularly for deoxyfluorination (Figure 4), include 
Phenofluor 15 
31
, PyFluor 16
32
 and nickel-fluorido complexes 17a and 17b 
33
 together with 
(diethylamino)difluorosulfonium tetrafluoroborate 18 (XtalFluor-E). 
34
. 
 
Figure 4. Deoxy-fluorinating reagent 15, PyFluor 16, nickel-fluorido complex 17, and XtalFluor E, 
18 
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3-New Methods for Monofluorination of Aryl Moieties 
 There are a large number of drugs and bioactive compounds that possess a fluorine atom 
appended to an aromatic ring.
1c
 Among recent fluorophenyl containing drugs are oral epidermal 
growth factor receptor (EGFR) Gefitinib 19 and Lapatinib 20, together with Vandetanib 21, an 
antagonist of the vascular endothelial growth factor receptor (VEGFR) and EGFR (Figure 5). 
 
Figure 5. Structures of Gefitinib 19, Lapatanib 20, and Vandetanib 21 
 
 While the vast majority of fluorinated pharmaceuticals are derived from fluoroaryl building 
blocks, the development of selective fluorination reactions or late-stage fluorination protocols 
1b,37
 
would be beneficial to the syntheses.  
 
 3a.- Conversion of CAr-H into CAr-F Bonds  
 Xu and co-workers 
38
 have developed an ortho C-H bond fluorination of 2-phenoxyl pyridine 
derivatives through a palladium-catalyzed reaction via 6-membered cyclopalladation mode using a 
removable directing group. This strategy has been applied to the synthesis of 2-phenoxyl nicotinic 
acid derivatives which are antagonists of the P2Y12 receptor, an important target in antiplatelet 
therapies 
39
, Scheme 1. 
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Scheme 1. ortho C-H bond fluorination of 2-phenoxyl pyridine derivatives through a palladium-
catalysis 
 
 The strategy 
38
 utilizes 2-phenoxypyridines as efficient phenol surrogates to undergo an ortho 
fluorination reaction. This method takes into account the strong coordinating ability of the pyridinyl 
directing group 
40
 that has been employed before in ortho-silylation, -arylation, -borylation, -
alkenylation, and acylation reactions. 
41
. The authors also extended the scope of the methodology 
towards the C-H fluorination of estrone derivative 22, as illustrated in Scheme 2 giving the 
fluorinated derivative 23 in 60% yield. 
 
Scheme 2. C-H fluorination of estrone derivative 
 
 3.b.-Conversion of CAr-X into CAr-F Bonds (X =  Cl, Br, I, OTf, NO2) 
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 Transition metal-complexes have been used to prepare fluoroarenes. 
42,35
. For instance, the 
palladium-catalyzed fluorination of aryl triflates bearing electron-withdrawing groups has been 
undertaken.
43
 The conversion of aryl stannanes 
44,35,45a
, trifluoroborates 
44
, boronic acids 
45c
, and 
silanes to aryl fluorides through silver or palladium catalysis and an electrophilic fluoride reagent has 
been reported. 
45
. 
 Ritter and co-workers 
46
 have accomplished the late-stage fluorination of a number of 
biologically- relevant substrates using a palladium fluoride complex which is easily synthesized from 
KF and a Pd organo-precursor.
46
 Thus, treatment of the palladium complex 24 with KF affords the 
palladium fluoride complex 25 in 90% yield within 5 min (Figure 6). 
46
. 
 
Figure 6. Synthesis of fluorinating reagent for late-stage fluorination  
 
An application of fluorinating reagent 25 is illustrated in Scheme 3 for the synthesis of 
fluorodeoxyestrone 27. 
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Scheme 3. Fluorination of deoxyestrone 26 by reagent 25 (see Figure 6) 
 
 This reagent can easily be employed for fluorination with 
18
F for PET (positron emission 
tomography) studies. 
46
 
 Hartwig and collaborators 
47,35
 have reported the fluorination of aryl iodides with a simple 
copper reagent and fluoride source. Reactions of (t-BuCN)2CuOTf and AgF with a range of aryl 
iodides are shown in Scheme 4. t-BuCN-ligated CuOTf was prepared in multi-gram quantities from 
Cu2O, triflic acid and t-BuCN. 
I
R R
F
(t-BuCN)2CuOTf (3 equiv)
AgF (2 equiv)
DMF, 140 oC, 22h
F
N
H
O
But N
F
F
40%                      59%                               50%                 56%
O
Ph
F
 
Scheme 4. Fluorination reaction of iodobenzenes with (t-BuCN)2CuOTf and AgF 
 
 The same combination of (t-BuCN)2CuOTf and AgF has also been employed by the same 
authors to achieve fluorination of aryl boronate esters. 
48
 
 More recently, Buchwald and co-workers 
49
 have reported the regioselective Pd-catalyzed 
fluorination of aryl triflates and bromides. The reaction involves the use of a fluorinated ligand in the 
presence of CsF in toluene or 2-MeTHF as solvent at room temperature. This new Pd- ligand 
complex (28, Figure 7) enables the fluorination reaction to be undertaken with high regiochemistry, 
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as opposed to other methods where a regioisomeric mixture of aryl fluorides was obtained. The 
structure of COD ligand is shown in Figure 7. 
 
Figure 7. Structure of Pd-complex for effecting highly regioselective fluorination of aryl bromides 
and triflates 
 
 The scope of the transformation and application to some biologically- active compounds is 
illustrated in Scheme 5.
49
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Scheme 5. Fluorination reaction of aryl triflates and bromides employing CsF or AgF in the presence 
of Pd-L COD complex (Figure 6) in 2-Me-THF or Toluene 
 
 Heteroaryl triflates were also suitable substrates. Notably, XAV939 29 
50,51
 a tankyrase 
inhibitor and potential cancer therapeutic, could be reacted to give the corresponding fluorinated 
product in excellent yield (Scheme 5), demonstrating the applicability of this method to medicinally-
relevant compounds. 
 A well-known reaction for the industrial preparation of aryl (and heteroaryl) fluorides is the 
nucleophilic aromatic substitution (SNAr).
52
 This involves the reaction of an electron-deficient 
(hetero)aryl halide or nitroarene with a nucleophilic fluoride source to generate the corresponding 
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aryl fluoride. 
53a 
 Anhydrous alkali metal fluorides (MF) are most typically employed as the fluoride 
source (usually CsF). However, these salts are poorly soluble in organic solvents. As a result, high 
temperatures and long reaction times are necessary to obtain high conversions. These forcing 
conditions often limit functional group tolerance and lead to the formation of undesired side 
products. 
52
 
 Sanford and co-workers 
53b
 have recently introduced the use of anhydrous tetramethyl 
ammonium fluoride Me4NF, as fluorinating reagent for halo(hetero)arenes in SNAr reactions. The 
reactions are carried out in DMF as solvent, at room temperature, and the yields are superior to those 
obtained when CsF or Bu4NF is used instead. The authors subjected relevant chloroarenes to the 
fluorination protocol and the products obtained are illustrated in Scheme 6. 
 
Scheme 6. Fluorination of haloarenes employing Me4NF in DMF at room temperature (24 h) through 
a SNAr reaction 
 
 As opposed to the observed low reactivity of aryl bromides and iodides in SNAr fluorination 
reactions
54
, Sanford and co-workers showed 
53b
 that aryl halides (and nitro-arenes) can react with 
NMe4F to afford comparable yields of the fluorinated product.
53b
 The relative rates of substitution 
were found to be NO2 ≫ Br > Cl > I ≫ OTf. 
 Ritter and co-workers 
31c
 have accomplished the deoxy-fluorination of aromatic and 
heteroaromaticcompounds employing Phenofluor 14 as fluorinating reagent. The scope of the 
transformation is illustrated in Scheme 7. 
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OH
IPr
N
IPr
N
F F
PrI
PrI
Phenofluor
CsF (3 equiv)
toluene or dioxane, 110 oC
F
F
N N
F
86%
F
89%
R
15
95%  
 Scheme 7. Deoxy-fluorination of aromatic compounds 
 
 Sulfonamides are well represented in a number of antibacterial, antimigraine, 
antiinflammatory and antidiabetic agents as well as diuretics. 
55
 Gouverneur and colleagues 
56
 have 
described an oxidative fluorination protocol of 4-t-butyl-substituted sulfonamides in the presence of 
PhI(OAc)2 (PIDA) and HF•Pyr as a fluoride source in DCM as solvent (Scheme 8).  
NHSO2R
1
t-Bu
R2
R3
1.-HF.pyr (1-4 equiv)
PIDA (1 equiv)
DCM, RT, 15 min
2.-TFA, RT, 5 min
NHSO2R
1
F
R2
R3
HN
O2
S
F 30, 61%
HN
O2
S
OMe
F 31, 59%
HN
O2
S
NO2
F 32, 65%
HN
O2
S
Cl
F 33, 58%
NHTs
Me
F
34, 68%
NHTs
Cl
F
35, 71%
NHTs
OMe
F
36, 22%
NHTs
F
CO2Me
37, 83%
NHTs
t-Bu
F
38, 71%  
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Scheme 8. Fluorination reaction of sulfonamides 
 
 Arylsulfonamides substituted with either electron withdrawing or releasing groups, afford the 
respected fluorinated products in similar yields (products 30-33). Aryl rings ortho-substituted with 
moderate releasing or attracting groups, afford fluorine substituted products in good yields (products 
34, 35, 37, 38), as opposed to strong electron donating groups on the aryl moieties, which afford poor 
yields (product 36). 
 Interestingly, 3.4-dihydro-2.1-benzothiazine 2,2-dioxide 39 activated with the t-butyl group at 
C-6 undergoes fluorination with PIDA and 4 eq. of HF-pyridine (Scheme 9). This reaction affords 40 
in 83% yield. A control experiment performed with the unsubstituted benzosultam 41 confirms that 
the presence of the t-butyl group on the substrate is necessary for formation of the desired product. 
 
Scheme 9. Oxidative fluorination of benzosultams 39 and 41 
 
 The authors investigated the mechanism of the reaction, and postulated an aryl-stabilized N-
sulfonylnitrenium intermediate, which undergoes nucleophilic fluorination. Addition of TFA re-
aromatizes the resulting fluorodienimine, with loss of t-butyl cation (Scheme 10).
56 
 
Scheme 10. Proposed reaction mechanism for the oxidative fluorination of sulfonamides 
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4.-Methods for Fluorination of Heteroaromatic Compounds 
 4.a.- Conversion of CHet-H into CHet-F Bonds 
  4.a.1.-Pyridine, Pyridazine, Pyrazine Derivatives  
 Hartwig and co-workers 
57
 have accomplished the late stage 
36,37
 CHet-H fluorination of a 
broad range of pyridines, quinolines, pyrazines, pyrimidines, and pyridazines with AgF2 to afford 
monofluorinated products (Scheme 11).  
N
R + AgF2
MeCN
rt,  hr
(0.05 M)         (3 equiv)
N
R
F
N F
O
42, 59%
N
Cl
FMe
43, 75%
N
Me Me
F
44, 44%
N
O
OMe
O
MeO
F
45, 63%
N F N F
Br46, 83% 47, 65%
N
N
F
48, 58%
N
NMe
Me F
49, 51%
N
N
N
N
N
N
N
N
F Me FF
NBoc
N
N
F Ph
F
OMe
OMe
50, 64%             51, 64%                     52,76%                 53, 78%                   54,  35%  
 
Scheme 11. Late stage fluorination reaction of pyridines, quinolines, pyrazines, pyrimidines, and 
pyridazines with AgF2 
  
 Benzoyl- and methylacetyloxy-substituted pyridines afford 2-fluorinated products in 
acceptable yields (products 42 and 45, Scheme 11). Pyridines substituted with chlorine- or methyl 
groups also afford good product yields (43 and 44). Quinolines, and pyrazine derivatives also render 
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good yields of ortho-fluorine substituted products (46-49), as is the case for pyrimidine and 
pyridazine substrates (50-54). 
 It should be noted that the fluorinated core of pyrazine (49, Scheme 11) has found recent 
applications in the treatment of influenza virus. 
58
 For instance, favipiravir (Figure 8) is an antiviral 
drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir is 
active against a broad range of influenza viruses, including A(H1N1), A(H5N1), and the recently 
emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to widely used antiviral 
drugs such as amantadine, rimantadine, and neuraminidase inhibitors and shows a synergistic effect 
in combination with oseltamivir, thereby enabling influenza treatment options to be expanded.  
 
Figure 8. Structure of favipiravir and related active pyrazine analog 
 
 The authors 
57
 next examined the late-stage fluorination with representative drugs.
57
 The 
fluorination of acetyl-protected tropicamide, an anticholinergic drug containing a base-sensitive 
acetate and an acidic α-phenyl amide, gave 55 in 70% isolated yield (Figure 9). t-Butyl 4-(3-methyl-
2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate, (a 1-(piperidin-4-yl)-
1H-imidazo[4,5-b]- pyridin-2-(3H)-one core found in more than 1000 calcitonin gene-related peptide 
(CGRP) receptor antagonists 
59
), afforded 56 in 82% yield. Furthermore, 3-(cyclopropylmethoxy)-N-
(2,6-dichlorophenyl)-4-(difluoromethoxy)-N-methylbenzamide reacted to form a 2-fluorinated 
analog of roflumilast 57, a drug used to treat chronic obstructive pulmonary disease. 
57
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Figure 9. Late stage fluorination to give F-tropicamide 55, F-1000 calcitonin 56, and F- roflumilast 
57 
  
 The authors 
57
 proposed a mechanism that involves initial coordination of AgF2 to pyridine, 
followed by addition of the [Ag]-F bond across the π system of the pyridine to form an amido-
silver(II)-fluoride complex58 (Scheme 12). The authors also observed a KIE of 2.9, suggesting that 
the coordination of pyridine to AgF2 and the addition step are reversible.  
 
N
+ AgF2
N
AgF2
N
AgF
H
F
F AgF
N F-2 AgF
-HF
58  
Scheme 12. Proposed reaction mechanism for the synthesis of 2-fluoropyridines with AgF2 
 
  4.a.2.- Pyrrole and Imidazole Derivatives 
Fluoro-substituted pyrroles have found important applications in medicinal chemistry. For 
instance, compound 59 (Figure 10) has potent anti-inflammatory activity and compound 60 has 
angiotensin II antagonist activity. 
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Figure 10. Fluoro-pyrroles with biological activity 
 
 Nenajdenko and collaborators have recently reviewed the fluorination methods for pyrrole 
derivatives. 
60
 N-Fluorodibenzenesulfonimide 11 (NFSI) was also used for the synthesis of 5-
fluorocamptothecin 62 – a derivative of the antitumoral and antileukemic quinoline alkaloid 61 
isolated from Camptotheca acuminate (Scheme 13).
60
 
 
Scheme 13. Synthesis of fluorocamptothecin 62 
 
Albertshofer and Mani 
61
 have recently accomplished the regioselective electrophilic 
fluorination of N-1-protected imidazole derivatives by quenching an intermediate lithio-species with 
NFSI at −78 °C.62 The transformation is illustrated in Scheme 14. 
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Scheme 14. Regioselective electrophilic fluorination of N-1-protected imidazolines 
 
  5.a.3.-Imidazoheterocyclic Derivatives 
 Imidazo[1,2-a]pyridines are important structural motifs in medicinal chemistry, such as 
zolpidem 63 
63,64
, alpidem 64 
65
, minodronic acid 65 
66
, olprinone 66 
67
, and zolimidine 67 
68
 (Figure 
11).The fluorination of imidazo[1,2-a]pyridines has recently been accomplished by Sun and co-
workers.
63
  
 
Figure 11. Therapeutic drugs containing the imidazo[1,2-a]pyridine nucleus 
 
 The authors 
63
 undertook a late-stage fluorination of the imidazo[1,2-a]pyridine core by 
employing Selectfluor as the fluorinating reagent, DMAP as a base in a mixture of CHCl3:H2O (3:1) 
starting the reaction at 0 
o
C for 2 h and then, allowing to reach room temperature (12 hour reaction). 
Some examples of this transformation are shown in Scheme 15. 
N
NR
1
R2
O
Et
LTMP, THF
-78 oC, then NFSI
5 min N
NR
1
R2
O
Et
F
R1 = Me, R2 = Cl, 62%
R1 = Ph, R2 = Cl, 61%
R1 = 4-Cl-Ph, R2 = Cl, 55%
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Scheme 15. Monofluorination of aryl-substituted imidazo[1,2-a]pyridines 
 
Imidazopyridines with electron releasing groups such as OMe proceeded in good yields 
(compound 69). Aryl-substituted imidazopyridines with halogen atoms on the aryl ring, also gave 
good yields of 3-fluorinated imidazo[1,2-a]pyridine derivatives (compounds 70-73). Notably, the 
antiulcer drug Zolimidine 67 was fluorinated in 87% yield to afford 3-fluoro-2-(4-
(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine 74. Halogenated imidazo[1,2-a]pyridines also afford 
good yields of 3-fluoro-substituted compounds (78 and 79). 
Next, the authors 
63
 explored the scope of imidazo-heterocycles such as those shown in 
Scheme 16, obtaining the respective fluoro-substituted compounds in excellent yields. 2-
Phenylimidazo[1,2-a]pyrimidine 80 affords 71% yield of 3-fluoro-2-phenylimidazo[1,2-a]pyrimidine 
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81, whereas 2-phenylbenzo[d]imidazo[2,1-b]thiazole 82 affords the 3-fluoro-substituted analog 83 in 
63% yield (Scheme 16). The reaction mechanism is depicted in Scheme 19. 
 
Scheme 16. Fluorination of imidazo heterocyclic derivatives 
 
 
Scheme 17. Proposed reaction mechanism for the 3-fluorination of imidazo[1,2-a]pyridines 
 
Taking into account literature precedent 
69
, the reaction proceeds through an electrophilic 
fluorination mechanism (Scheme 17). Initially, reaction of imidazo[1,2-a]pyridine 84 with 
Selectfluor 7 yields the unstable 3-fluorinated cation 85, followed by addition of water to form 86. 
Deprotonation follows to generate intermediate 87, and then a proton is abstracted by DMAP to 
furnish the monofluorinated product 88.
63
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 4.a.4.-Isoxazolinone Cores 
The fluorination of oxygen- and sulfur-containing heterocycles has recently been reviewed by 
O´Sullivan and co-workers. 
70
 Isoxazolinone cores are widespread components in numerous 
biological important molecules such as those depicted in Figure 12. 
 
 
Figure 12. Representative isoxazolinone cores in pharmaceutical drugs 89 and 90 are of natural 
origin; 91 and 92 are of non-natural origin 
 
The fluorination of isoxazolinone cores has recently been developed by Wang and co-
workers. 
71
 The authors 
71
 have accomplished the stereoselective fluorination through the use of an 
asymmetric catalyst 93 (a bis-cinchona alkaloid 
72
), NFSI as fluorinating agent, in the presence of 
K3PO4, in CHCl3 at -50 °C. Yields of 4-fluorinated product range from 78 to 93% with enantiomeric 
excess ranging from 73-83% (Scheme 18). 
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Scheme 18. Stereoselective fluorination of isoxazolinones 
 
  4.a.5.-Synthesis of Benzoxazine Cores 
Benzoxazines are present in bioactive compounds, such as the anxiolytic and anticonvulsant 
drug etifoxine 100 
74,73
, or progesterone receptor agonists 101 (Figure 13). 
 
Figure 13. Bioactive compounds 100 and 101 containing the 4H-3,1-benzoxazine core 
 
 The fluorination of 4H-3,1-benzoxazine core has been developed by Guo and co-workers, 
73
 
through electrophilic fluorocyclization 
75
 of styryl amides. The optimal conditions used Selectfluor 
reagent, in MeCN at room temperature under atmosphere of nitrogen. The scope of the 
transformation is illustrated in Scheme 19. 
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R1
NH
O R2
R
Selecfluor
(1.1 equiv)
MeCN, r.t. N
O
R2
FR1
R
N
O
F
NO2
102, 75%
O
53%
S
86%
71% 90% 53%
70% 76% 83%
N
O
F
N
O
F
N
O
F
iBuN
O
F
COPhN
O
F
N
O
FPh
PhN
O
FPh
Cl
PhN
O
F
F
 
Scheme 19. Synthesis of fluorinated 4H-3,1-benzoxazine cores from styryl-amide precursors  
 
  4.b.-Conversion of CHet-X into CHet-F Bonds (X = Cl, Br, I, OH, OTf, NO2) 
   4.b.1.-Pyridine, Pyridazine, Pyrazine, Imidazole and Triazole Derivatives 
 As mentioned in Section 3a, Sanford and co-workers 
53b
 developed anhydrous Me4NF for 
SNAr fluorination of appropriate halo-precursors (Cl, Br, I). These conditions have been extended to 
halo-(hetero)aromatic starting materials (Figure 14). Pyridines with electron withdrawing groups 
yield fluoro-substituted products 103-105 in good yields. Chloroquinoline, chloroisoquinoline, 
chloropyridazine and chloropyrazine substrates also undergo room-temperature fluorination to form 
fluorinated products 106-110, respectively, in excellent yields. The high-yielding synthesis of 8-
(benzyloxy)-2-fluoroquinoline 107 is particularly noteworthy, as 
18
F-107 has been used for the PET 
imaging of amyloid plaques. 
76,77
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N
H3CO
F
CO2
iPr
103, 93%
N
N
F
F
106, 79%
N
N
F
109 90%
N F
NC
N
N
F
        110, 92%
N
Cl
F
F
CO2
iPr
104, 89%
N F
OBn
107, 91%
105, 94%
108, 78%  
Figure 14. SNAr fluorination of chloropyridine, isoquinoline, chloropyridazine and chloropyrazine 
substrates with Me4NF 
 
 Ritter and co-workers 
31c
 have accomplished the deoxy-fluorination of heteroaromatic 
compounds employing Phenofluor 15 as fluorinating reagent. The scope of the transformation is 
illustrated in Scheme 20. 
N N
NCl
Cl
F
F
F
113, 93%        114, 71%
Z
X
Y
OH
IPr
N
IPr
N
F F
PrI
PrI
Phenofluor
CsF (3 equiv)
toluene or dioxane, 110 oC
Z
X
Y
F
N
N F
115, 78%
N
N
F
116, 34%
N
Br
F
111, 32%
N
N
F OH
117, 57%
15
112, 53%
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Scheme 20. Scope of the deoxyfluorination reaction of quinolines, isoquinolines, pyrazines and 
pyrimidine derivatives with Phenofluor 
 
 Quinolines, isoquinoline, quinoxaline and pyrimidine starting materials gave good yields of 
fluorine-substituted products, whereas pyridine and quinazoline starting materials afforded lower 
yields of the desired products (Scheme 20). 
Terconazole 118, fluconazole 119, cyproconazole 120, and triazolam 121 (Figure 15) are 
representative of marketed drugs containing a triazole.
78
 
 
 
Figure 15. Triazoles in clinical use 
 
 The fluorination of triazole nuclei has recently been carried out by Chu and co-workers 
79
, 
starting from 5-iodotriazole, and employing AgF (5 equiv), TMEDA (tetramethyl ethylene diamine, 
0.2 equiv), in toluene at 110 
o
C for 20 h. 
79
 The scope of the reaction is illustrated in Figure 16. 
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 Figure 16. Scope of the fluorination of triazole derivatives 
 
 1,4-Disubstituted triazoles afford good yields of 5-fluorotriazole derivatives 122 and 123. 
Triazoles substituted with methylpyridine, n-heptyl, methylnaphthalene at the 1-position (and a 
phenyl group at the 4-position) also afford good yields of 5-fluorotriazole derivatives (products 124-
126). 
 
5.-Methods for Fluorination of Sugars and Nucleobase Derivatives 
80
 
 Fluorination also has long been recognized in nucleoside chemistry, and the synthetic origin 
can be traced back to a report by Fox and co-workers. 
81
 The replacement of the 2′ or 3′ hydroxyl 
groups of a nucleoside with a fluorine atom causes only a minor change in the overall structure, but 
profoundly affects the stereoelectronic properties of the sugar moiety. 
82
 Such dominating effects can 
control the conformational equilibria 
5,6
 and lock the sugar ring into either a North, 127 (C3′- endo 
pucker) or a South, 128 (C2′-endo pucker) conformation, 83 that can stabilize the glycosidic bond 
toward hydrolysis, 
84
 and can also modulate the octanol/water partition coefficient (Log P) (Figure 
17). 
85
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Figure 17. North 127 (C3′- endo pucker) or a South, 128 (C2′-endo pucker) conformations of 
carbohydrates 
 
 A recent finding 
5
 has shown that compounds that mimic the C3′-(F) endo pucker of the 
native acyl adenylate intermediate 
6
 exhibit greater biological activity than compounds that adopt the 
C2′-endo pucker, thus establishing a strong relationship between bioactivity and conformation for 
inhibitors of the nucleoside antibiotic 5′-O-[N-(salicyl)sulfamoyl]-adenosine, which  is a prototype 
for a new class of antibiotics that targets iron acquisition through inhibition of aryl acid adenylating 
enzymes 
5
. 
 The introduction of a fluorine atom into a piperidine can also alter the pKa significantly, 
resulting in an improvement to oral bioavailability. 
86
 For instance, the 3-piperidinylindole derivative 
129 (Figure 18) binds to the human 5-HT2A serotonin receptor, and was targeted as a promising 
antipsychotic drug lead. 
87
 However, the bioavailability of 129 was limited due to the basicity of the 
secondary amine group (positively charged at physiological pH). This inconvenience has been 
overcome by introducing a fluorine atom onto the piperidine ring (130, Figure 18), reducing the 
basicity of the secondary amine by nearly two orders of magnitude, resulting in a marked betterment 
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of the oral bioavailability. The bioavailability (and 5-HT2A binding affinity) could be further 
improved by the introduction of a second fluorine atom, this time onto the indole moiety (131, Figure 
18); this further improvement in bioavailability was attributed to deceleration of the metabolic 
degradation. 
86a
   
 
Figure 18. Fluorination improves the bioavailability of 3-piperidinylindole derivatives 129-130 by 
reducing the basicity of the secondary amine 
 
 Shaw and collaborators
30b
 achieved the enantioselective fluorination reaction of piperidinones 
taking advantage of the methodology reported by MacMillan
86b
 , which uses a modified cinchona 
alkaloid catalyst. The authors found that primary chiral amines are superior as chiral inductors than 
secondary amines. Thus (R)-1-(2-methoxyphenyl)ethanamine is able to induce a high ee, as shown in 
Scheme 21. On the other hand, (R)-2-amino-1,1,2-triphenylethanol affords the opposite enantiomer 
with high ee, albeit lower yields (Scheme 21). With these catalysts, similar yields are obtained to 
those for the quinine derivatives shown in Figure 19. 
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Scheme 21. Enantioselective fluorination of piperidinone 
 
 
Figure 19. Structure of cinchona alkaloid-derived catalysts 
 
The triphenylethanolamine catalyst shows the highest level of ee of all the commercial 
catalysts, which is in line with the observation that increasing the steric environment around the 
amine improves the ee; however, the conversions are low, which may also be a result of the sterically 
encumbered environment of the catalyst. The authors
30b
 also confirmed that when carrying out the 
reaction  at 0 
o
C, the amount of catalyst could be reduced from the original 20 to 10% without any 
drop in yield or ee. When NFSI is replaced by Selectfluor as fluorinating reagent, the reaction failed 
to yield any fluorinated product. The refinements in the reaction allowed the procedure to be scaled- 
up to produce 23g of enantiopure 1-Boc-3S-fluoro-4R-piperidinol. 
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 Iminosugars can competitively bind to glycosidase enzymes because of their structural 
resemblance to the terminal sugar moiety of natural substrates. As a consequence, iminosugars show 
great promise for the treatment of a variety of diseases including diabetes, viral infection, bacterial 
infection, and lysosomal storage disorders. 
88
 
 Miglitol (132, Figure 20) is an orally-available drug used for the treatment of type II diabetes 
(Merck). The fluorinated analogue 133 (Figure 20) is particularly worthy of note, since this 
compound is five times more potent than the existing drug 132, and exhibits no toxicity in human 
cells. 
89
 
 
Figure 20. Structures of Miglitol and fluorinated analog 
 
 A general strategy for the synthesis of fluorinated N-heterocycles is the deoxy-fluorination 
method using reagents illustrated in Figure 4.
31b
  C2´, C3´, and C5´-Fluoronucleosides have been 
synthesized with the use of Selectfluor 
90
 and NFSI, and some selected examples with Selectfluor are 
shown in Scheme 22. It should be noted that  there are also numerous approaches for fluorination of 
nucleosides that involve readily prepared fluorinated building blocks 
91
 that will not be discussed. 
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Scheme 22. Fluorination of nucleosides with Selectfluor 
 
 There has been a recent review article on the synthesis of fluorinated nucleoside derivatives 
91
, where the sugar moiety can be fluorinated through the use of DAST, Selectfluor, or FClO3, etc. 
 Fluorinated nucleosides have found an array of applications in medicinal chemistry. 2 ,2´ -
Difluorocytidine 134 (gemcitabine) 
92
 belongs to the most widespread applied therapeutics in 
combination with radiotherapy, against a number of cancers (Figure 21). 
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Figure 21. Structures of fluorinated nucleobase and nucleosides currently employed in medicinal 
chemistry 
 
 The synthesis of gemcitabine 134 has been revisited and improved recently.
93,94
 Sofosbuvir 
135 (Figure 21) has been approved as a therapeutic agent for the treatment of hepatitis C. Among 
other fluorinated nucleosides with antiviral activity, are: FddC 136 (2′,3′-dideoxy-2′-fluorocytosine) 
95
 and FLT 137 (3′-fluoro-3′-deoxythymidine) 96 which inhibit the HIV reverse transcriptase. In 
addition, there is one other nucleoside fluorinated at the 2′-position of the sugar moiety approved by 
the FDA for the treatment of cancer: clofarabine 138 (2-chloro-2′-deoxy-2′- fluoroarabinoadenosine) 
which is used clinically for the treatment of leukemia in children. 
97
 
 Ferrero and co-workers 
98
 have recently studied the synthesis of fluorinated azanucleosides 
and investigated their biological activity against HIV-1LAI using 3′-azido-3′-deoxythymidine (AZT, 
zidovudine) as a reference in an assay with human peripheral blood mononuclear cell (PBM). The 
representative compounds are illustrated in Figure 22. Compounds 139-141 show modest activity 
when compared to AZT. 
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Figure 22. Examples of azanucleosides investigated against HIV-1 
 
   
 Zajc and co-workers 
99
 have come up with a straightforward method for the introduction of a 
fluorine atom into the 8-position of ribonucleosides via metalation-electrophilic fluorination under 
heterogeneous reaction conditions. The scope of the transformation is illustrated in Scheme 23. 
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Scheme 23. Fluorination of ribonucleosides and 2´-deoxyribonucleodises 
 
 Fluorinated nucleosides 143-147 formed through a SN process were obtained with all the 
substrates. The presence of the secondary products 148-151 suggests an ET (electron transfer) 
process. Thus, a competing nucleophilic substitution reaction and an ET process results in the 
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mixture of observed products. 
99
 In the case of ribonucleosides, it is likely that the SN reaction is 
slower due to steric reasons. 
 As a new family of anti-HIV compounds, emtricitabine FTC 152 (4-amino-5-fluoro-1-
[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one) and racivir RCV 153 
(4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one) 
(Phase II), contain a F atom. Figure 23 illustrates their structures.
100 
 
 
 
Figure 23. Structures of Emtricitabine and Racivir 
 
 6.-Fluorination of sp
3
 Carbon Atoms 
  6.a.-Fluorination of benzylic positions 
 Methods for the fluorination of benzylic carbon atoms have been recently reviewed by Hurley 
and co-workers. 
101
 
 The beneficial properties of benzyl fluorides in lead optimization 
102,103
 have motivated an 
intense research activity in late stage fluorination of benzylic positions. 
101
 Britton and colleagues 
104
 
have reported a late-stage fluorination of benzylic positions employing NFSI using either a 
decatungstate photocatalyst or AIBN-initiation. 
They applied the method to the synthesis of fluorinated ibuprofen, as shown in Scheme 24. 
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Scheme 24. Fluorination of ibuprofen methyl ester  
  
W10O32
4-
W*
h
R1
H
R2
W10O32
5-H+
R1 R2
(PhSO2)2NH
(PhSO2)2N F
154
156
(PhSO2)2N
155
R1
F
R2
 
Scheme 25. Photocatalytic mechanism for the late-stage fluorination of benzylic positions 
 
 The mechanism for the photocatalytic reactions is illustrated in Scheme 25. Irradiation of 
photocatalyst tetrabutyl ammonium decatungstate (TBADT) produces an excited species (W*) that 
abstracts a H atom from a benzylic position, producing a benzylic radical 154. Radical 154 abstracts 
a fluorine atom from NFSI, producing the fluorination at the benzylic position and 
bis(benzenesulfonimide) radical 155. Radical 155 accepts a H atom from 156, regenerating TBADT 
and closing the photocatalytic cycle. 
 Groves and co-workers 
105
 have developed a manganese-catalyzed oxidative C-H fluorination 
reaction of benzylic position and applied the fluorination strategy to medicinal targets and 
compounds with biological activity such as ibuprofen and vitamin E. The general strategy involves 
the use of a manganese-salen complex 157 (Scheme 26), triethylamine trihydrofluoride (TREAT-HF, 
Figure 3) or AgF, in MeCN as solvent. Interestingly, no fluorination of the aryl moiety is 
encountered.  
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R1
H
R2
N N
O O
Mn
Cl
But tBu
tBu But
157
157 (20 mol%)
PhIO, MeCN, 50 oC
TREAT-HF (1.2 mmol) or
TREAT-HF (0.4 mmol) +
AgF (2.4 mmol)
R1
F
R2
F
O
O
55%, antiinflammatory
F-ibuprofen methyl ester
F NHPh
COOMe
48%, d.r. = 5:1
non-natural amino acid
F-homophenylalanine
F
O
AcO
53%, d.r.= 2.2:1
Vitamin E analog
158
159
 
Scheme 26. Late-stage benzylic fluorination employing Mncatalyst A, AgF and TREAT-HF  
 
 From Scheme 26 it can be observed that F-ibuprofen methyl ester 158 is obtained in 55% 
yield, and the F-vitamine E 159 analog in 53% yield. 
The authors 
105
 proposed a mechanism for the above reaction, as illustrated in Scheme 27. 
The starting [Mn
III
(salen)F] or [Mn
III
(salen)F2]
_
 catalyst, formed in situ, is oxidized to 
[Mn
V
(O)(salen)F], which then abstracts a hydrogen atom from the substrate, forming the benzyl 
radical and a manganese(IV) species (Scheme 27). Then, the formed radical reacts with the 
[Mn
IV
(salen)F2] complex, yielding the fluorinated products, regenerating the Mn
III
 catalyst. An 
important kinetic isotope effect (5.6±0.6) was observed for a 1:1 mixture of ethylbenzene and 
ethylbenzene-d10 as the substrate. The relatively low enantioselectivities observed (Scheme 26) are 
probably due to a very early transition state for the fluorine transfer step and a linear Mn–F–C 
geometry. However, the fact that the asymmetric Mn catalyst can lead to a good stereoinduction, 
provides strong evidence for a manganese-bound fluorine source in the fluorine transfer step. 
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Mn
F
F
N N
O O
F
Mn
F
N N
O O
Mn
F
N N
O O
O
Mn
OH
F
N N
O O
H  
Scheme 27. Proposed mechanism for the catalyzed benzylic fluorination  
 
 Xu and co-workers 
106a
 have recently developed a fluorination method for benzylic positions 
(and -carbonyl compounds, vide infra) employing 15 mol% of Pd(OAc)2, NFSI as fluorinating 
agent, Ag2O, and pivalic acid in chlorobenzene as solvent at 90 °C. The scope of the transformation 
is illustrated in Scheme 28. 
 
Scheme 28. Palladium-mediated benzylic fluorination reaction 
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 The 8-aminoquinoline-derived auxiliary is acting as a directing group for the -fluorination of 
the amide group. 
106a
 Fluorination of benzenepropanamide derivative gave good yields of product 
160 (Scheme 28). The authors 
106a
 examined additional substrates bearing halogen substituents such 
as o-Cl, p-F, and 2,4-diCl. All of them gave similar yields of products 161-163. Starting materials 
containing electron-withdrawing substituent including m-NO2, m-CF3, or electron releasing m-OCH3 
also render a good yield of fluorinated product under the reaction conditions (products 164-166, 
respectively). 
 
 6.b.-Fluorination of Steroids 
106b
 and Prostaglandine Derivatives 
 Fludrocortisone 167 
107
 was one of the first fluorinated pharmaceutical drug to be developed 
(Figure 24). A more recent variety is fluticasone propionate 168, an antiinflammatory steroidal drug 
used to treat a variety of conditions. 
 
 
Figure 24. Structure of fludrocortisone 167. Structure of fluticasone propionate 168 
 
 Fluticasone propionate 168 can be applied to treat inflammation associated with dermatoses 
and psoriasis. 
108
  
  
Page 41 of 75 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
42 
 
 Lee and co-workers have recently employed NFSI for the fluorination pathway of betulinic 
acid derivative 169 
109
, according to Scheme 29. Betulinic acid derivatives 169 possess potent anti 
HIV activity. 
 
Scheme 29. Fluorination step in the synthesis of betulinic acid derivative 169, with potent anti HIV 
activity 
 
 Steroids have recently been reported to undergo a deoxy-fluorination reaction with PyFluor 
with high diastereoselectivity, as illustrated in Scheme 30. 
32
 
 
Scheme 30. Deoxyfluorination of steroid derivatives employing PyFluor 
 
 
2
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A laboratory-devised fluoro pyridinium 171 has been employed for the fluorination of an 
analog 172 of Corey lactone prostaglandin synthetic intermediate, as illustrated in Scheme 31. 
 
Scheme 31. Fluorination of Corey lactone prostaglandin synthetic intermediate 172 
 
 A fluorinated prostaglandin currently employed in the treatment of glaucoma is tafluprost 173 
(Figure 25). This prostanoid is a very potent intraocular pressure-lowering agent as a result of FP-
receptor agonist activity.
110
 
 
Figure 25. Structure of tafluprost 173, a fluorinated prostanoid with FP-receptor agonist activity 
 
 
 The synthesis of tafluprost 173 has been achieved 
111
 by fluorination of a lactone 
prostaglandin derivative 174, as illustrated in Scheme 32. 
Page 43 of 75 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
44 
 
 
Scheme 32. Synthesis of tafluprost  
  
 The synthesis of tafluprost was started from the Corey aldehyde 174, which was converted to 
enone 176 by Horner–Emmons reaction with phosphonate 175. The fluorination reaction of enone 
176 with morpholinosulfur trifluoride 177 
110
 in CHCl3 at 30–40 °C for 82 h and successive 
deprotection of the benzoyl group with potassium carbonate in MeOH gave geminal difluoride 178 
in 71% yield. Reduction of lactone 178 with 
i
Bu2AlH in THF–toluene at -78 °C and ulterior Wittig 
reaction with the ylide prepared from 4-carboxybutyltriphenylphosphonium bromide (179) and 
reactions using potassium bis(trimethylsilyl)amide or sodium bis(trimethylsilyl)amide as the base in 
THF at 0 °C, afforded product 173 with the Z/E stereoselectivity in a 99:1 ratio. The Wittig reaction 
and successive esterification of the crude acid treated with isopropyl iodide and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in acetone gave the desired 15-deoxy-15,15-difluoro-PGF2a 
isopropyl ester 173 (tafluprost) in 72% yield.  
 
 6.c.-Fluorination of terpene-derivatives 
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 Tang and collaborators 
112
 have recently reported a new methodology to carry out the 
fluorination of sp
3
 carbon atoms of biological relevant substrates. The fluorination of sclareolide 
180, a sesquiterpene lactone used as supplement in weight loss therapy, has been accomplished 
through the use of radical initiator K2S2O8, Selectfluor II (Figure 3), in MeCN/H2O mixtures, 
according to Scheme 33. Fluorination does not take place at the two methine positions due to steric 
hindrance. Instead, the regioselective fluorination takes place at the C-2 methylene position, which 
has less steric impediment. 
 
Scheme 33. Late-stage fluorination of sclareolide 180 
 
 Also, the fluorination of gibberellic-derivative GA 181 
112
 (a diterpene, that stimulates the 
cells of germinating seeds to produce mRNA molecules that code for hydrolytic enzymes), can give 
42% yield of fluorinated product 182 (Scheme 34). 
 
Scheme 34. Late stage fluorination of gibberellic 181 derivative 
 
 In gibberellic 181, fluorination at the C16 methine position occurs as the major product due 
to a more electron-rich and less steric hindered site compared to the other tertiary C–H bonds. 112. 
Page 45 of 75 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
46 
 
 With an ester derivative of the anticancer drug taxol 183 (Scheme 35) 
112
, fluorination takes 
place with 4.0 equiv. of K2S2O8 and 2.5 equiv. of Selectfluor II (PF6) to furnish the fluorinated 
product 184 in 33% isolated yield. The selective and late-stage fluorination occurred at the methine 
position on the side chain due to the steric hindrance and deactivation of the other available tertiary 
C–H bonds on the rings. It is also noteworthy that the alkene and free hydroxyl groups were not 
fluorinated under the reaction conditions. 
 
 
Scheme 35. Late stage fluorination of taxol derivative 183 
 
 The proposed mechanism for all the transformations in Schemes 33-35 is depicted below in 
Scheme 36. 
112
  
 
Scheme 36. Proposed reaction mechanism for the radical fluorination of sp
3
 C atoms with Selectfluor 
 
 It is accepted that peroxydisulfate anion decomposes into the sulfate radical anion 
113
 which 
oxidizes an aliphatic C-H bond into a carbon radical 186 (Scheme 36), ensuing electrophilic 
fluorination. Otherwise, Selectfluor is also known to fluorinate alkyl radicals 186 to form C-F bonds. 
114
.  
Page 46 of 75Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
47 
 
 
 7.d.-Fluorination of sp
3
 carbon atoms by photocatalysis 
 DiRocco and Britton 
115
 have reported the photocatalytic fluorination of sp
3
 carbon atoms to 
be applied the methodology to the synthesis of odanacatib 189, used in the treatment for 
osteoporosis and bone metastasis. Compound 189 is an inhibitor of cathepsin K, an enzyme involved 
in bone resorption. The sodium salt of decatungsten 188 is able to catalyze the fluorination of salts of 
leucine methyl ester in the presence of NFSI. The large scale production of odanacatib 189 was 
carried out in a flow photoreactor while irradiating at 365 nm (Scheme 37). 
116
 
 
Scheme 37. Fluorination of leucine methyl ester towards the synthesis of odanacatib 189 
 
 The mechanism of the reaction is depicted in Scheme 25 (vide supra). 
 
 6.e.-Fluorination at the α-Carbonyl Positions 117 and -Carbonyl Positions 106 
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 Shibata and colleagues 
28
 have recently shown that the fluorinating reagent N-
fluoromethanesulfonimide (F–N(SO2Me)2, Me-NFSI, Figure 3) is a better fluorinating reagent for 
methane groups than NFSI. The authors compared a set of fluorination reactions of methane 
positions with Me-NFSI and NFSI and demonstrated improved scope and higher yields with the 
former. They have applied the new reagent to the fluorination reaction of -keto-esters 190, as 
illustrated in Scheme 38. 
 
Scheme 38. Fluorination reaction of -keto-esters with Me-NFSI 
 
 The enantioselective incorporation of fluorine atoms into organic substrates was pioneered by 
Shibata and co-workers. 
118
 The authors 
118
 employed combinations of cinchona alkaloids and NFSI 
or Selectfluor as fluorinating reagents. Shaw and collaborators have accomplished the enantioselctive 
fluorination of piperidinones in good yields and excellent ee
86b,30b
 (vide supra, Scheme 21, section 5) 
based on the studies of MacMillan and collaborators. 
 The enantioselective incorporation of fluoroacetate into organic molecules is a prevailing 
matter. Acetate is one of the most fundamental building blocks in nature and organic synthesis, from 
which numerous natural products and medicinally important compounds, such as polyketides and 
statins are formed. Saadi and Wennmers 
119
 have very recently employed the fluoromalonic acid 
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hemi-thioethers 191 (F-MAHTs, Figure 26) as equivalents of activated fluoroacetate. This F-MAHTs 
191 is the fluorinated versions of nature´s acetate building blocks. 
 
Figure 26. Structure of racemic fluoromalonic acid hemi-thioethers F-MAHTs 191, and catalyst 192 
(a quinidine-urea catalyst) and its enantiomer 193 
 
 F-MAHT 191 in the presence of catalyst 192 or 193 (Figure 26) together with 4-
dimethylaminopyridine (DMAP) increased the enantioselectivity towards the synthesis of F-MAHTs 
(Scheme 39). 
 
Scheme 39. Aldehydes and their decarboxylative aldol reaction of F-MAHTs 
 
 In this respect, the authors 
119
 were able to synthesize fluorinated atorvastatin 194 
120
 in good 
yields and with 99% enantiomeric excess, as shown in Scheme 40. 
Page 49 of 75 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
50 
 
 
Scheme 40. Synthesis of enantioselective fluorinated atorvastatin 194 
 
 Sanford and co-workers 
121
 have recently reported a stereoselective fluorination strategy to 
achieve the synthesis of chiral fluorolactam building blocks (196, Figure 27) towards the synthesis of 
potential pre-clinical candidate spleen tyrosine kinase inhibitors Syk 195. 
122
 
 
Figure 27. Spleen tyrosine kinase inhibitors Syk, and chiral fluorolactam building blocks B 
 
 Fluoromalonate ester 197 (Scheme 41) is synthesized in high yield through direct fluorination 
reaction of dimethyl malonate ester using fluorine gas, catalyzed by copper nitrate in MeCN solution. 
Michael addition of acrylonitrile to fluoromalonate 197 affords the desired nitrile 198 in 90% yield. 
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Ulterior reduction of the nitrile group of 198 by hydrogen over palladium and subsequent base-
catalyzed ring closure yielded racemic fluorolactam 199 (Scheme 41).  
 
Scheme 41. Synthesis of racemic fluoromalonate 199 
 
 The authors 
121
 used CAL-B 10 000 (a recombinant Candida Antartica Lipase B that is 
commercially available and used to catalyze a range of biotransformations) to give the desired 
fluorolactam 200 in > 99% e.e. (Scheme 42). 
 
Scheme 42.  Synthesis of enantioselective fluorolactam 200 employing Candida Antartica Lipase B 
 
 More recently, Stuart and co-workers 
30
 have come up with a fluorination method of 1,3-
dicarbonyl compounds employing fluoroiodane 14, according to Scheme 43. 
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Scheme 43. Fluorination of 1,3-dicarbonyl compounds with 1-fluoro-1,3-dihydro-3,3-dimethyl-1,2-
benziodoxole 14 
 
 In a disconnected approach, De Kimpe and co-workers 
124,125
 have employed ethylbenzoyl 
fluoroacetate 201 for the construction of 4-fluoropyrazolones 202 and their ulterior reduction to 3-
hydroxy-4-fluoropyrazoles 203, according to Scheme 44. Such pyrazole cores are present in 
numerous pharmacologically-active compounds. 
 
 Scheme 44. Synthesis of 3-hydroxy-4-fluoropyrazole derivatives 
 
 Britton and co-workers have prepared a range of flavone derivatives in order to evaluate their 
potential as anti-prostate cancer agents 
126
 through -fluorination of 1,3-dicarbonyl derivatives. They 
successfully incorporated fluorine into 204 using NFSI, affording fluorinated adduct 206 in 37% 
yield (Scheme 45). Acidification of 205 led to spontaneous cyclisation and elimination of water to 
furnish fluoroflavone 206 in excellent yield. 
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Scheme 45. Fluorinated adduct 206 with anti-prostate cancer activity 
 
 A recent method for the enantioselective -fluorination of carbonyl compounds (aldehydes) 
has been developed by Sun and coworkers. 
127
 The authors 
127
 used the Bode catalyst 207 (Scheme 
46), NFSI as both fluorinating and oxidizing agent, K2CO3 as the base, in CHCl3 at room 
temperature.  
 
R
O
207 (20 mol%), K2CO3 (3 equiv)
NFSI (3 equiv), R´OH (1.1 equiv)
CHCl3, RT, 48 h
R CO2R´
F N
O
N
N
Mes
Cl-
207
Ph CO2Me
F
CO2Me
F
MeO2C
MeO
CO2Me
F
63%, 93% ee              65%, 93% ee                            65%, 94% ee
CO2Me
F
N
CO2Me
F
CO2Me
F
S
75%, 94% ee                  62%, 95% ee                        63%, 93% ee  
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Scheme 46. Scope of the enantioselective -fluorination of aldehydes 
 
 Heterocycles, such as the easily oxidizable pyridine and thiophene, were also compatible with 
the strongly oxidative reaction conditions. 
127
 The authors 
127
 also applied the strategy to the 
synthesis of -fluoroamides and thioesters, starting with aldehydes and making them react with 
nucleophiles such as amines and thiols. 
 Statines, or β-hydroxy-γ-amino acids, are important components of several key peptides. 
These peptides usually function as protease inhibitors and therefore are relevant substrates for the 
treatment of various diseases including cancer (cathepsin D), Alzheimer’s disease (cathepsin D, 
BACE, α- secretase), hypertension (renin), AIDS (HIV protease), and malaria (plasmepsins). 128 As a 
result, the synthesis of both natural statines and their analogues has been a subject of intense interest. 
Hunter and coworkers 
129
 have designed a diastereoselective synthesis of 2-(R) and 2-(S) 
fluorostatines represented in Scheme 47. 
 
Page 54 of 75Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
55 
 
BocN
O O
1.- Catalyst C (5 mol%)
      NFSI, MTBE
2.-NaBH4 BocN
O OH
BocN
O OH
F F
+
64%, dr > 20:1 with (R)-209 = N
H
OTMS
Ar
Ar
, dr = 1:7 with (S)-209 =
N
H
OTMS
Ar
Ar
Catalyst
62%
BocN
O O
BocN
O OH
BocN
O OH
F F
+
60%, dr < 1:20 with (R)-209 =
N
H
OTMS
Ar
Ar
43%, dr = 3:1  with (S)-209 =
N
H
OTMS
Ar
Ar
208
1.- Catalyst C (5 mol%)
      NFSI, MTBE
2.-NaBH4
Catalyst
 
Scheme 47. Diastereoselective fluorination of protected statines 
 
 The reaction started with protected leucine, and the fluorination took place from chiral 
aldehyde 208 (Scheme 47) employing NFSI as fluorinating reagent, organocatalysts 209  (i.e.: (R)-2-
(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, (R)-209  and (S)- 2-
(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, (S)-209) in methyl t-butyl ether as solvent 
(MTBE), and further reduction with NaBH4. The (R)-209 organocatalyst afforded the highest 
diastereoselective ratios of protected fluoro-statine. Deprotection took place with HCl. 
129
 
 Xu and coworkers 
106
 have developed a protocol for introducing a fluorine atom into the -
position of carbonyl compounds. They employed catalyst Pd(OAc)2, NFSI as fluorinating source, 
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pivalic acid, in chlorobenzene as solvent at 80 °C. The scope of the transformation is depicted in 
Scheme 48. 
N
N
H
O
R
H
Pd(OAc)2 (15 mol%)
NFSI (2 equiv), Ag2O (1 equiv)
PivOH (1 equiv)
chlorobenzene, 80-120 oC, 1h
N
N
H
O
R
F
N
N
H
OF
58%
N
N
H
OF
43%
N
N
H
O
N
50%
Cbz
F
N
N
H
O
F
F
47%
N
N
H
O
N
F
F
45%
Cbz N
N
H
OF
50%  
Scheme 48. Scope of the synthesis of fluorinated of -carbonyl compounds 
 
 The proposed mechanism 
106
 is illustrated in Scheme 49. 
N
N
H
O
Pd(OAc)2
PivOH
2PivOH
N
N
O
PdII
F N(SO2Ph)2
N
N
O
Pdiv
F N(SO2Ph)2
2PivOH
N
N
H
O
F
NH(SO2Ph)2 +
210
211
212
 
Scheme 49. Proposed reaction mechanism for the synthesis of fluorinated of -carbonyl compounds  
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 The first step involves the formation of the cyclopalladated intermediate 210 (Scheme 49) to 
afford the [5,5]-fused bicyclic. Then, Pd
II
 is oxidized into a Pd
IV
 intermediate by NFSI and Ag2O. 
The role of PivOH in this reaction is presumably to help reductive elimination of strong 
metal−fluorine bond by replacing the N(SO2Ph)2 ligand on Pd
IV
 complex or to help regenerate the 
active catalyst by replacing the N(SO2Ph)2 ligand on Pd
II
. Finally, reductive elimination of 211 forms 
the fluorination product 212 with ulterior regeneration of Pd
II
.  
 Thus this β-C(sp3)−H fluorination of carbonyl compound derivatives such as carboxylic acids 
can provide a new method for the introduction of fluorine atom into a drug candidate which is of 
great value for SAR studies.
1f,n
 
 
 
6.f.-Synthesis of α- and -Fluoroamine Cores with Pharmacological Activity 
 The rationale behind the special treatment in fluorinating techniques for amines is the 
decrease in their basicity upon introducing a vicinal fluorine atom, and modulation of 
physicochemical characteristics, such as Log P. Incorporation of the fluorine substituent at a late 
stage of the transformation is also desirable.
130
. 
 Chen and Liu have very recently presented a review article on methods for accessing -
fluoroamines. 
93
 These -fluoroamines constitute important structural motifs in a large array of 
biological important molecules. Figure 28 illustrates some relevant -fluoroamine bioactive 
compounds: LY503430 213; MK-0731 214; antibacterial agent 215, and GABA-AT inactivator 216. 
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Figure 28. Relevant -fluoroamines bioactive compounds 213-216 
 
A general strategy to prepare -fluoroamines using Selectfluor, is illustrated in Scheme 50. 
 
 
Scheme 50. Ritter-type amino-fluorination of olefins 
131
 
 
 The reaction depicted in Scheme 50 belongs to a Ritter-type aminofluorination reaction or a 
fluoroamination reaction. 
29
 In this reaction, 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) (NFTh, 13) was used as electrophilic fluorinating reagent (Figure 3), while the 
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solvent MeCN functions as nucleophile. Both tetramethylethene and styrenes successively gave 
vicinal fluoroamides in good yields. 
 Shibata and co-workers have used FP-T300 (compound 6 in Scheme 51) as a fluorinating 
reagent for the synthesis of bioactive fluorobrevianamide E 217 and fluorogypsetin 218. 
25,86
 
 
 
Scheme 51. Synthesis of -fluoroamines fluorobrevianamide E 217 and fluorogypsetin 218 
employing FP-T300 6 (1-fluoro-2,4,6-trimethyl pyridinium triflate)  
 
 The strategy was also employed for the synthesis of fluorinated -carboline fragments. 26 
A carbocation is involved in the electrophilic fluorination process. These transformations rely on the 
electrophilic incorporation of fluorine atom and a subsequent cyclization process. 
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 For transition metal-catalyzed formation of -fluoramino compounds, the review from Chen 
and Liu is quite comprehensive. 
93
 Thus, transition metals such as Pd , Ag, Au, Fe and Cu, have been 
shown to catalyze aminofluorination reactions 
93
, enabling the syntheses of fluoro-piperidines, -
pyrrolidines, -pyrroles, -quinolones, -isoquinolines, -lactams, -pyrazoles, -oxazolidinones, and 
fluorinated indoles. The fluorinating agents employed in this fluorinating reaction were Selectfluor 
or NFSI. 
 More recently, Chen and Liu 
132
 have accomplished the fluorination reaction of piperidine 
cores through an aminofluorination reaction 
75
 with high stereoselectivity. They applied the 
methodology towards the synthesis of 6-(R)-fluoroswansonine 219 (an anticancer alkaloid with 
potential to treat glioma and gastric carcinoma, and also an adjuvant for other anticancer drugs) and 
5-(R)-fluorofebrifugine 220 (with antimalarial properties). The synthetic targets are depicted in 
Scheme 52. 
 
Scheme 52. Fluorination reaction towards the synthesis of F-swansonine and F-ferifugine 
 
7.-Fluorination of sp
2
 Carbon Atoms 
 Gulder and co-workers 
133
 have reported the synthesis of the pharmacologically interesting 
heterocycles 4-fluoro-1,3-benzoxazepines from o-styryl benzamides by employing a fluorination/aryl 
migration/cyclization cascade strategy. 
75
 The protocol avoids the need for transition metal catalysts, 
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and uses a shelf-stable hypervalent fluoro iodane reagent as an electrophilic source of fluorine. This 
reagent is not only significantly more reactive than the well-established iodine(III)-based fluorinating 
reagent Selectfluor, but provides completely different chemoselectivity, providing seven-membered 
ring benzoxazepines instead of oxazines. Moreover, this strategy is used in the synthesis of 20 
structurally distinct congeners and proceeds with complete regioselectivity under mild reaction 
conditions, according to Scheme 53. 
133
 The reaction employs the shelf-stable crystalline fluoro-
benzoiodoxole 14 and consists of a fluorination / aryl migration / cyclization steps.
75 
 
Scheme 53. Fluorinated benzoxazepine derivatives 221 
 
8.-Fluorination of sp Carbon Atoms 
 For the biological-relevant synthesis of fluorinated isoquinoline nuclei, the silver-catalyzed 
reaction 
134
 of alkynes in the presence of NFSI is illustrated in Scheme 54. 
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Scheme 54. Ag-catalyzed fluorination of alkynes by NFSI 
 
In the reaction, a fluorinated isoquinolinium intermediate 222 (Scheme 54) is derived from 
the oxidative fluorination of an heteroaryl-silver complex. The t-butyl substituent is eliminated as 
isobutene in the presence of weak base (Li2CO3).  
 When the t-butyl group 
134
 was changed to a CH2CO2R group, a fluorinated isoquinolinium 
intermediate is obtained instead, which can act as a 1,3-dipolar reagent. In the presence of base, and 
together with an alkyne, a 3+2 cycloaddition can yield biologically-interesting nuclei,  such as 
pyrrolo[2,1-a]isoquinolines (Scheme 54). When CF3 alkynes were used, the pyrroloisoquinoline 
products  show remarkable regioselectivity and excellent yields. 
 
9.-Conclusions 
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The introduction of new and easy-to-handle commercial fluorinating reagents, either of nucleophilic 
or electrophilic in nature, has tamed the reactivity of fluorine gas for fluorination reactions and, 
therefore, made protocols more direct and less cumbersome. However, there still remains the need 
for fluorinating reagent strategies that could be easily prepared from inorganic fluoride salts as 
opposed from fluorine gas, as is the case with the majority of commercial electrophilic fluorinating 
reagents. Although the mechanism for fluorination with electrophilic fluorinating reagents remains a 
matter of some debate, with possibly both polar and radical components, the reactions have shown 
substantially improved yields over alternative processes, and opened-up an array of activity for the 
application of these reagents on diverse families of compounds. Thus, electrophilic fluorination 
strategies for aromatic compounds as well as for heteroaromatic compounds have been the subject of 
many literature reports. These strategies describe homolytic aromatic substitution reactions or 
replacement of groups such as halides, triflates, or boronic acids, with fluorine. Fluorination of 
aliphatic substrates has also been shown to proceed with electrophilic reagents, albeit through 
different mechanisms, on sp
3
, sp
2
, and sp carbon atoms. However, there still remains the challenge 
for stereoselective introduction of fluorine atoms into Csp
3
 centres 
Nucleophilic fluorination strategies with nucleophilic fluorinating reagents have been employed in 
the fluorination of (hetero)aromatic substrates, mainly through SNAr reactions, and for the ipso 
substitution of hydroxy-substituted (hetero)aromatic compounds. 
Table 1 summarizes the different applications of both electrophilic and nucleophilic reagents for the 
fluorination of different families of organic compounds. Denoted in red is the atom or group to be 
substituted by F, or position of addition of the fluorine moiety. As opposed to the reactions illustrated 
in the text above, Table 1 classifies the transformations according to fluorinating reagent for a quick 
reference guide to reagent applications. 
 
 
Page 63 of 75 Organic & Biomolecular Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
03
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 N
or
th
er
n 
Ill
in
oi
s U
ni
ve
rs
ity
 o
n 
03
/0
8/
20
16
 1
0:
14
:4
4.
 
View Article Online
DOI: 10.1039/C6OB00764C
64 
 
Table 1. Different fluorination strategies most commonly employed for medicinal targets. In red is 
the group to be replaced by fluorine atom or position of addition of the fluorine atom 
reagent Organic 
family 
Additive Conditions Substrate Ref. 
NFSI, 11 aryls Pd(dba)2 EtOAc, 80-110 
o
C 
 
[38] 
NFSI, 11 pyrroles LHDMS THF, -78 
o
C 
 
[60] 
NFSI, 11 imidazoles LTMP THF, -78 
o
C 
 
[61] 
NFSI, 11 isoxazolino-
nes 
bis-cinchona 
alkaloid 
(stereospecific 
fluorination) 
K3PO4, CHCl3, 
-50 
o
C 
 
[71] 
NFSI, 11 pyrrolidinon-
es 
i
PrNH, BuLi THF, -78 
o
C 
 
[98] 
NFSI, 11 nucleobases LDA Solid NFSI 
S = sugar and deoxysugar 
[99] 
NFSI, 11 benzylic 
positions 
tetrabutylammoniu
m-  
decatungstein 
(TBADC) 
NaHCO3, 
MeCN 
λ = 365 nm, 
flow system 
 
[104] 
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NFSI, 11 methine 
positions 
Na4W10O32 (cat.) MeCN : H2O 
(9 : 1) 
λ = 365 nm 
 
 
 
[115] 
NFSI 11 or 
Me-NFSI 12 
-carbonyl 
positions 
LDA  THF,-78 
o
C–
RT; 
 
[109] 
[28] 
[127] 
[129] 
[126] 
NFSI, 11 -carbonyl 
positions 
Pd(AcO)2, Ag2O 
Pivot  
chlorobenzene, 
80-120 oC 
 
[106] 
NFSI, 11 sp carbon 
atoms 
AgNO3, Li2CO3 DMA, 60 
o
C 
 
[134] 
SelectFluor, 
7 
imidazohete-
rocyclic cores 
DMAP CH3Cl:H2O, 
3:1 
0 
o
C-RT 
 
[63] 
Selectfluor, 
7 
methylene 
and methine 
carbon atoms 
K2S2O8 MeCN : H2O, 
50 
o
C 
 
[112] 
Selectfluor, 
7 
sp
2
 carbon  
atoms 
- MeCN, RT 
 
[73] 
Selectfluor, 
7 
carbohydrat-
es 
- MeCN, RT  
 
[90] 
[92] 
[93] 
[95] 
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14 
-carbonyl 
positions 
Et3N.3HF 24 h, 40 
o
C 
DCM 
 
[30] 
 
14 
sp
2
 carbon 
atoms 
MS, 4 A MeCN 
 
[133] 
AgF aryl iodides (t-BuCN)2CuOTf DMF, 140 
o
C, 
22h 
 
[47] 
[35] 
AgF aryl triflates 
or bromides 
Pd-L complex 
COD, KF or CsF  
Me-THF 
 
[49] 
AgF iodotriazoles - MeCN 
 
[79] 
AgF2 pyridines, 
pyrazines, 
pyridazines 
and 
pyrimidines 
- 
MeCN 
 
[57] 
Me4NF pyridines, 
pyrazines, 
pyridazines 
and 
pyrimidines 
- 
MeCN 
 
[53b] 
Phenofluor 
15 
phenols and 
hydroxyheter
oaromatics 
CsF toluene or 
dioxane, 110 
o
C  
[31c] 
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